Assessing Concurrent Adherence to Combined Essential Medication and Clinical Outcomes in Patients With Acute Coronary Syndrome. A Population-Based, Real-World Study Using Group-Based Trajectory Models.
acute coronary syndrome
clinical outcomes
concomitant medications
concurrent adherence
group-based trajectory models
population-based cohort
real-world data
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
01
2022
accepted:
21
03
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Adherence to multiple medications recommended for secondary prevention of cardiovascular conditions represents a challenge. We aimed to identify patterns of concurrent adherence to combined therapy and assess their impact on clinical outcomes in a cohort of patients with acute coronary syndrome (ACS). Population-based retrospective cohort of all patients discharged after hospitalization for ACS (2009-2011), prescribed ≥3 therapeutic groups within the first month. We assessed monthly concurrent adherence (≥24 days of medication out of 30) to ≥3 medications during the first year, and patterns were identified through group-based trajectory models. A composite clinical outcome during the second year was constructed. The association between adherence patterns and traditional refill adherence metrics [e.g., the proportion of days covered (PDC)], and outcomes were assessed through a multivariable Cox proportional hazards model. Among 15,797 patients discharged alive, 12,057 (76.32%) initiated treatment with ≥3 therapeutic groups after discharge. We identified seven adherence trajectories to ≥3 medications: Adherent (52.94% of patients); Early Gap (6.64%); Middle Gap (5.67%); Late Decline (10.93%); Occasional Users (5.45%); Early Decline (8.79%); Non-Adherent (9.58%). Compared to the Adherent group, patients belonging to Early Gap (HR:1.30, 95%CI 1.07;1.60), Late decline (hazards ratio (HR): 1.31, 95% CI 1.1; 1.56), and Non-Adherent trajectories (HR: 1.36, 95% CI 1.14; 1.63) had a greater risk of adverse clinical outcomes, which was also different to the risk ascertained through concurrent PDC < 80 (HR: 1.13, 95% CI 1.01; 1.27). Overall, seven adherence trajectories to ≥3 drugs were identified, with three distinct adherence patterns being at higher risk of adverse outcomes. The identification of patterns of concurrent adherence, a more comprehensive approach than traditional measurements, may be useful to target interventions to improve adherence to multiple medications.
Identifiants
pubmed: 35694663
doi: 10.3389/fcvm.2022.863876
pmc: PMC9174582
doi:
Types de publication
Journal Article
Langues
eng
Pagination
863876Informations de copyright
Copyright © 2022 Rodríguez-Bernal, Sánchez-Saez, Bejarano-Quisoboni, Hurtado, García-Sempere, Peiró and Sanfélix-Gimeno.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2016 Aug 23;11(8):e0161381
pubmed: 27551748
Med Care. 2013 Sep;51(9):789-96
pubmed: 23685406
Clin Pharmacol Ther. 2018 Jun;103(6):1052-1060
pubmed: 28875569
Circulation. 2013 Jan 29;127(4):e362-425
pubmed: 23247304
J Am Geriatr Soc. 2017 Apr;65(4):747-753
pubmed: 27991653
Ann Nutr Metab. 2014;65(2-3):205-10
pubmed: 25413659
Circulation. 2014 Dec 23;130(25):e344-426
pubmed: 25249585
Am J Med. 2007 Aug;120(8):713-9
pubmed: 17679131
Arch Intern Med. 2011 May 9;171(9):814-22
pubmed: 21555659
J Chin Med Assoc. 2021 Dec 1;84(12):1084-1091
pubmed: 34561408
Heart Lung. 2015 Jul-Aug;44(4):299-308
pubmed: 25766041
J Am Coll Cardiol. 2017 Sep 26;70(13):1543-1554
pubmed: 28935030
J Gen Intern Med. 2016 Sep;31(9):1052-60
pubmed: 27229000
Am Heart J. 2015 Jul;170(1):62-9
pubmed: 26093865
J Manag Care Pharm. 2013 Apr;19(3):247-57
pubmed: 23537459
Am J Hypertens. 2017 Oct 1;30(10):1015-1023
pubmed: 28535297
Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1105-13
pubmed: 25903307
J Manag Care Spec Pharm. 2016 Nov;22(11):1349-1361
pubmed: 27783548
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Ophthalmology. 2015 Oct;122(10):2010-21
pubmed: 26319441
Annu Rev Clin Psychol. 2010;6:109-38
pubmed: 20192788
Am Heart J. 2018 Mar;197:153-162
pubmed: 29447776
Hypertension. 2020 Jun;75(6):1334-1357
pubmed: 32370572
Circulation. 2014 Feb 18;129(7):754-63
pubmed: 24326988
Eur J Prev Cardiol. 2017 Jun;24(3_suppl):44-51
pubmed: 28618914
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Int J Epidemiol. 2020 Jun 1;49(3):740-741e
pubmed: 31977043
Am J Manag Care. 2009 Jul;15(7):457-64
pubmed: 19589013